Conference Coverage

Your guide to ASH 2018: Abstracts to watch


 

Notable posters

Dr. Iberia Romina Sosa is with Baylor College of Medicine in Houston Courtesy Baylor College of Medicine

Dr. Iberia Romina Sosa

Iberia Romina Sosa, MD, PhD, of Baylor College of Medicine in Houston, suggested several posters worth visiting in the areas of thrombosis and bleeding.

Poster 1134 looks at the TNF-alpha driven inflammation and mitochondrial dysfunction in the platelet hyperreactivity of aging and MPN.

How do you know if your therapy for thrombotic thrombocytopenic purpura is working? Poster 3736 examines the measurement of cell-derived microparticles as a possible tool to monitor response to therapy.

You don’t have to be taking aspirin to have a bleeding profile characteristic with consumption of a cyclooxygenase inhibitor. Poster 1156 provides a first report of a platelet function disorder caused by autosomal recessive inheritance of PTGS1.

Poster 2477 takes a closer look at fitusiran, an antithrombin inhibitor, which improves thrombin generation in patients with hemophilia A or B. Protocol amendments for safety monitoring move fitusiran to phase 3 trials, Dr. Sosa said.

Pages

Recommended Reading

FDA expands approval of brentuximab vedotin to PTCL
MDedge Hematology and Oncology
ASH 2018 coming attractions look at the big picture
MDedge Hematology and Oncology
Cortactin expression aids in CLL-MCL differential
MDedge Hematology and Oncology
FDA approves biosimilar rituximab for NHL
MDedge Hematology and Oncology
ASH expands late-breaking abstract session
MDedge Hematology and Oncology
CAR T-cell studies to be presented at ASH
MDedge Hematology and Oncology
Biosimilar deemed equivalent to rituximab in FL
MDedge Hematology and Oncology
Elderly NHL patients have higher NRM after HSCT
MDedge Hematology and Oncology
Bortezomib may overcome resistance in WM
MDedge Hematology and Oncology
R-CHOP effective as first-line treatment in FL
MDedge Hematology and Oncology